Check out these bold predictions of winners and losers!
November 4, 2000
Trend number ten: Biotech
Functional genomics makes drug discovery cheaper and faster, reinvigorating all of biotech.
herring.com
<Consequences:
Now that the human genome is mapped, biotech startups are racing to profit from it. The field of functional genomics will change the way scientists discover and develop drugs, making the process faster, cheaper, and smarter.
Winners:
Functional genomics companies that offer innovative approaches and new analytical tools to improve our understanding of the relationships between genes, proteins, diseases, and drugs: Rosetta Inpharmatics (Nasdaq: RSTA), Illumina (Nasdaq: ILMN), Athersys (proposed Nasdaq: ATHX), Millennium (Nasdaq: MLMN), Celera (NYSE: CRA), Affymetrix.
Losers:
Companies that fail to make the transition to the post-genomic era: Orchid Bio-sciences (Nasdaq: ORCH), Lyon Biosciences, Aurora Bioscience (Nasdaq: ABSC), Human Genome Sciences (Nasdaq: HGSI). > |
